Shawn Singh, VistaGen CEO (Jason Koerner/Getty Images for Concordia Summit)

Vista­Gen faces an­oth­er fail as anx­i­ety drug flops a PhI­II study — shares crater

Vista­Gen Ther­a­peu­tics’ so­cial anx­i­ety drug flopped in a Phase III tri­al, the com­pa­ny an­nounced Fri­day, adding to its list of pro­grams that haven’t panned out.

The tri­al, which en­rolled 209 pa­tients ac­cord­ing to clin­i­cal­tri­als.gov, did not sig­nif­i­cant­ly change pa­tient-re­port­ed anx­i­ety lev­els com­pared to place­bo. In the tri­al, pa­tients di­ag­nosed with so­cial anx­i­ety dis­or­der took ei­ther Vista­Gen’s drug, PH94B, or a place­bo, and then were chal­lenged with a five-minute pub­lic speak­ing tri­al, dur­ing which they were asked to rate their anx­i­ety.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.